Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Leqembi is a prescription amyloid beta-directed antibody containing lecanemab-irmb. It is indicated for Alzheimer disease and is started in patients with mild cognitive impairment or mild dementia. Amyloid beta pathology is confirmed before treatment.
read more about leqembi ...Lecanemab-irmb is a monoclonal antibody that binds aggregated soluble and insoluble forms of amyloid beta. Treatment reduces amyloid beta plaques in the brain.
Leqembi is used in patients with Alzheimer disease at the mild cognitive impairment or mild dementia stage after confirmation of amyloid beta pathology. Apolipoprotein E epsilon 4 testing is performed before treatment to inform the risk of amyloid-related imaging abnormalities.
Starting treatment can use 10 mg per kg by intravenous infusion every two weeks or 500 mg by subcutaneous injection once weekly. After 18 months, the starting regimen can continue or transition to maintenance with 10 mg per kg intravenously every four weeks or 360 mg subcutaneously once weekly. Intravenous infusions run for about one hour.
Leqembi carries a boxed warning for amyloid-related imaging abnormalities with edema or hemosiderin deposition. Serious, life-threatening, and fatal events can occur, including intracerebral hemorrhage. A brain MRI is obtained before treatment and after one, two, three, and six months of therapy. Hypersensitivity, infusion reactions, and injection reactions can also occur.
Leqembi treats Alzheimer disease and is started at the mild cognitive impairment or mild dementia stage.
Starting treatment uses either 10 mg per kg intravenously every two weeks or 500 mg subcutaneously once weekly.
Treatment can continue on the starting regimen or transition to 10 mg per kg intravenously every four weeks or 360 mg subcutaneously once weekly.
Yes. The boxed warning concerns amyloid-related imaging abnormalities, including serious or fatal brain swelling and bleeding events.
DailyMed - LEQEMBI (lecanemab-irmb) injection and LECANEMAB AUTOINJECTOR. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975. Date Accessed October 8, 2026.
FDA Approves First At-home Starting Dose for Alzheimer's Disease Treatment. U.S. Food and Drug Administration. https://content.govdelivery.com/accounts/USFDA/bulletins/4205a72. Date Accessed October 8, 2026.
Lecanemab-irmb Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a623004.html. Date Accessed October 8, 2026.
Lecanemab-irmb. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Lecanemab-irmb. Date Accessed October 8, 2026.
LEQEMBI (lecanemab-irmb) Prescribing Information. Eisai. https://www.eisaimedicalinformation.com/-/media/Files/Leqembi/Prescribing-Information.pdf. Date Accessed October 8, 2026.